Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Beta Bionics (BBNX) Gains from Sales and Divestitures (2025 - 2026)

Beta Bionics' Gains from Sales and Divestitures history spans 2 years, with the latest figure at $72616.0 for Q1 2026.

On a quarterly basis, Gains from Sales and Divestitures changed N/A to $72616.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $72616.0, a N/A change, with the full-year FY2025 number at $275919.0, changed N/A from a year prior.
Gains from Sales and Divestitures hit $72616.0 in Q1 2026 for Beta Bionics, down from $275919.0 in the prior quarter.
Over the last five years, Gains from Sales and Divestitures for BBNX hit a ceiling of $275919.0 in Q4 2025 and a floor of $72616.0 in Q1 2026.